SUMO2/3 antibody (AA 1-93)

Catalog No. ABIN7596052

The Mouse Monoclonal anti-SUMO2/3 antibody has been validated for WB, IF, FACS, ELISA and ICC. It is suitable to detect SUMO2/3 in samples from Human.

Quick Overview for SUMO2/3 antibody (AA 1-93) (ABIN7596052)

Target: SUMO2/3 (Small Ubiquitin Related Modifier 2/3 (SUMO2/3))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This SUMO2/3 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), ELISA, Immunocytochemistry (ICC)

Clone: AT10F1

Product Details anti-SUMO2/3 Antibody

Binding Specificity: AA 1-93

Purpose: Human SUMO 2/3 antibody

Immunogen: Recombinant human SUMO2 (1-93aa) purified from E.coli

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: Phosphate-Buffered Saline ( pH 7.4) with 0.02 % Sodium Azide, 10 % glycerol

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Target Details for SUMO2/3

Target: SUMO2/3 (Small Ubiquitin Related Modifier 2/3 (SUMO2/3))

Alternative Name: SUMO 2/3

Background: SUMO (small ubiquitin-related modifier) is the best-characterized member of a growing family ofubiquitin-related proteins. 8-11 kDa that covalently modify various intracellular proteins. It resemblesubiquitin in its structure, its ability to be ligated to other proteins. SUMO regulates cellular function of avariety of target proteins. SUMO proteins are expressed as their precursor forms. Cleavage of the residuesafter the GG region of these precursors by SUMO-specific proteases in maturation is a prerequisite forsubsequent sumoylation. Notably, SUMO2 and SUMO3 precursors have 96 % sequence identity, and recentstudies have shown protein substrates conjugated with SUMO2 or SUMO3 have similar, if not identical,biological consequences.

NCBI Accession: NP_008868